Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed uterine confined endometrioid endometrial adenocarcinoma with one of the following:
• * Grade 2 or 3 carcinoma with more than 50% myometrial invasion (stage IC and IIA)
• * Grade 2 or 3 carcinoma with stromal invasion of the cervix (stage IIB)
• No grade I adenocarcinoma
• Less than 50% papillary serous or clear cell histology on pathologic specimen
• Prior hysterectomy (total abdominal, vaginal hysterectomy, or laparoscopic-assisted vaginal hysterectomy) and bilateral salpingo-oophorectomy with or without additional surgical staging for endometrial cancer no more than 8 weeks prior to study
• No known metastatic extrauterine metastases, known gross residual disease, positive peritoneal cytology, or distant metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Zubrod 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,800/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 10 g/dL
• Hepatic:
• Bilirubin no greater than 1.5 times normal
• SGOT no greater than 3 times normal
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• No cardiac dysrhythmias
• Other:
• No other malignancy within the past 5 years except nonmelanomatous skin cancer
• No medical contraindications to study therapy
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior chemotherapy
• Endocrine therapy:
• Not specified
• Radiotherapy:
• No prior radiotherapy
• Surgery:
• See Disease Characteristics